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Background: Imaging has become a routine part of heart failure (HF) investigation. Echocardiography is a first-line
test in HF given its availability and it provides valuable diagnostic and prognostic information. Cardiac magnetic
resonance (CMR) is an emerging clinical tool in the management of patients with non-ischemic heart failure.
Current ACC/AHA/CCS/ESC guidelines advocate its role in the detection of a variety of cardiomyopathies but there
is a paucity of high quality evidence to support these recommendations.
The primary objective of this study is to compare the diagnostic yield of routine cardiac magnetic resonance versus
standard care (that is, echocardiography with only selective use of CMR) in patients with non-ischemic heart failure.
The primary hypothesisis that the routine use of CMR will lead to a more specific diagnostic characterization of the
underlying etiology of non-ischemic heart failure. This will lead to a reduction in the non-specific diagnoses of
idiopathic dilated cardiomyopathy and HF with preserved ejection fraction.
Design: Tertiary care sites in Canada and Finland, with dedicated HF and CMR programs, will randomize consecutive
patients with new or deteriorating HF to routine CMR or selective CMR. All patients will undergo a standard clinical
echocardiogram and the interpreter will assign the most likely HF etiology. Those undergoing CMR will also have a
standard examination and will be assigned a HF etiology based upon the findings. The treating physician’s impression
about non-ischemic HF etiology will be collected following all baseline testing (including echo ± CMR). Patients will be
followed annually for 4 years to ascertain clinical outcomes, quality of life and cost. The expected outcome is that the
routine CMR arm will have a significantly higher rate of infiltrative, inflammatory, hypertrophic, ischemic and ‘other’
cardiomyopathy than the selective CMR group.
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Discussion: This study will be the first multicenter randomized, controlled trial evaluating the role of CMR in non-
ischemic HF. Non-ischemic HF patients will be randomized to routine CMR in order to determine whether there are
any gains over management strategies employing selective CMR utilization. The insight gained from this study should
improve appropriate CMR use in HF.
Trial registration: NCT01281384.
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Innovations in imaging create the potential for earlier, less
invasive and more accurate diagnoses of disease and may
ultimately improve health outcomes. However, imaging is
also one of the fastest growing health care expenditures.
The 2005, the US Medicare Payment Advisory Committee
found that the growth of cardiac imaging was nearly
double any other cardiac procedure [1]. This underscores
the need to ensure efficient development, implementation
and use of this health care resource in order to provide
value to patients and society. However an evaluation of
the clinical and economic impact of cardiac imaging has
lagged behind the pace of the technology. A recent review
of current ACC/AHA guidelines found that only 11% of
recommendations provide level of evidence A (multiple
randomized controlled trials and meta analyses) and 48%
have level of evidence C (consensus opinion) [2]. In
cardiac diagnostics, level of evidence A is found in only
2%, level of evidence C in 17% and in 44% of recommen-
dations there is no evidence provided. These observations
underscore the need for more evidence based trials, par-
ticularly in cardiac imaging.
In 2007, the Canadian Institutes of Health Research
New Frontiers Program consensus conference identified
the urgent need for improved evaluation of imaging in
relation to outcomes and translation from bench to bed-
side, particularly in heart failure (HF). In response, we
established IMAGE-HF, a synergistic multi-disciplinary,
multi-modality, multi-center Canada-Finland team com-
prised of seven Canadian sites and three Finnish sites. The
main goal of IMAGE-HF is to evaluate cardiac imaging
using existing clinical practice strategies for HF and their
links to relevant outcomes (level 1 projects) and to create
a unique translational platform for the evaluation of novel
imaging biomarkers in animal models of HF and in HF
patient populations (level 2 and 3 projects). IMAGE-HF
1-B, rOUTine versus Selective MAgnetic Resonance in
non-ischemic HearT Failure-HF (OUTSMART-HF), will
study the role of cardiac magnetic resonance (CMR) in
non-ischemic heart failure.
Statement of the problem
Population studies reveal that 50% of HF patients have pre-
served ejection fraction (HFPEF) and a dismal prognosissimilar to those HF patients with reduced ejection fraction
(HFREF) [3-5]. Among the HFREF patients, 50% have no
significant underlying coronary artery disease [6]. The
most common identifiable causes for non-ischemic HF
include hypertension, valvular heart disease, arrhythmia,
post-viral and acquired or inherited cardiomyopathies.
However, standard measures of cardiac morphology and
function obtained on imaging testing provide only limited
information about HF etiology or prognosis [7] and, other
than ejection fraction (EF), have a limited role in thera-
peutic decision-making.
Echocardiography is well suited for the assessment of
HF patients because it is widely available and provides
reliable information on cardiac performance in normal
and diseased states. It is also considered the best imaging
modality for valvular disease, a significant finding in 35%
of patients hospitalized with HF [8]. More recent techno-
logical advances such as tissue velocity and strain have
shed new insights into pathophysiological mechanisms
that may be particularly pertinent in HFPEF [9-11]. Fur-
thermore, diastolic dysfunction determined by Doppler
echocardiography is common in HF patients and has been
shown to be a predictor of increased mortality during
longitudinal follow-up [12]. Data from the Rochester
Epidemiologic Program revealed that there was a lower
risk of death in HF patients who had undergone echocar-
diograms compared to those who had not, suggesting that
echocardiography improved care and should be part of
the routine investigation of HF patients [13]. Given the
available evidence and its extensive clinical experience,
echocardiography is recommended as a class 1 indication
in the initial investigation of all HF patients [14-16].
CMR is emerging as a valuable tool in the diagnosis of
non-ischemic heart failure and is considered preferable or
at least equivalent to other diagnostic tests in several
cardiomyopathies [17]. Ventricular volumes and function
derived from CMR is more accurate than standard echo-
cardiography due to high inter-test and inter-observer
reproducibility [18]. Moreover, CMR offers insight into
myocardial tissue characteristics [19], with specific re-
gional patterns of myocardial injury [20]. Non-infarct and
infarct patterns have been reported in 28% and 13%,
respectively, of patients with HF and unobstructed coro-
nary arteries [19]. In a recent single site study of 120
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differentiating an ischemic from a non-ischemic etiology
[21]. CMR has been used to characterize myocarditis
[22-24], sarcoidosis [25], hypertrophic cardiomyopathy
[26], hemochromatosis [27] and amyloidosis [28]. CMR
thus offers a new class of diagnostic and prognostic
parameters for personalized therapy and prevention of
HF. However, there is a need to understand how such data
impacts diagnosis, clinical decision-making and patient
outcomes.
The diagnosis of HFPEF remains challenging as dis-
cussed in negative drug trials to date [29-31]. Diagnostic
criteria incorporating clinical signs and symptoms, bio-
markers, imaging and/or hemodynamic parameters have
been proposed but not studied well [32]. Diffuse myocar-
dial fibrosis as assessed by CMR has been utilized as a
novel diagnostic target in HF [33] and cardiomyopathy
subjects [34]. Patients with HFPEF are known to have
increased myocardial collagen and fibrosis and hence
CMR could be used to study this group.
Despite growing evidence of the utility for CMR in
various cardiomyopathies, a comprehensive study exa-
mining its role in HF is lacking.
Objectives
Primary objective
To compare the diagnostic yield of routine cardiac mag-
netic resonance versus standard care (that is, echocar-
diography with only selective use of CMR) in patients
with non-ischemic heart failure. The diagnostic cate-
gories of HF to be considered in this study include:
idiopathic dilated cardiomyopathy, infiltrative cardio-
myopathy, inflammatory cardiomyopathy, hypertrophic
cardiomyopathy, heart failure with preserved ejection frac-
tion (HFPEF), ischemic cardiomyopathy, mixed etiology
and ‘other’ (for example, pericardial disease, adult con-
genital heart disease, arrhythmogenic right ventricular
cardiomyopathy).
Secondary objectives
To determine the effects that routine use of CMR in
non-ischemic HF has on therapeutic decisions on the
Composite Clinical Endpoint (CCE), cardiac function,
symptoms, quality of life (QoL), and costs. Ancillary
measurements will include the safety of imaging tests
and adverse reactions to gadolinium contrast agent.
Hypotheses
Primary hypothesis
Routine use of CMR (versus selective use) will lead to a
more specific diagnostic characterization of the under-
lying etiology of non-ischemic heart failure. This will
lead to a reduction in the non-specific diagnoses of idio-
pathic dilated cardiomyopathy and HFPEF.Secondary hypotheses
Routine use of CMR will have a significant impact on
treatment decisions, and will (1) lead to more disease spe-
cific therapies and/or (2) cause a significant change in the
number and class of HF medications, during follow-up.
The routine CMR group will also have improved clinical
outcomes (CCE), symptoms and QoL and decreased costs
compared to the standard of care group during follow-up.
Design
Randomized controlled trial comparing i) routine CMR
to ii) echocardiography with selective CMR in patient
with HF due to a non-ischemic cardiomyopathy (NICM)
and/or HFPEF. Among patients enrolled in level 1 of
IMAGE-HF, it is expected that 504 will have known
NICM (or strongly suspected based on young age,
absent risk factors and presenting history) and/or HFPEF
(Figure 1).
Tertiary care sites (in Canada and Finland) with
dedicated HF programs will participate in the study
(Additional file 1). Consecutive patients will be enrolled
at sites with CMR programs (defined as a minimum 200
cases/year) and randomized to routine CMR or selective
CMR. Non-ischemic HF patients from sites with smaller
CMR programs will be included in a registry of patients
undergoing routine HF care (that is, selective use of
CMR). All sites will receive approval from local ethics
committees (UOHI REB protocol # 2010422-01H) and
patients will give written informed consent. Participants in
the selective CMR arm may only undergo CMR when
there is a suspicion or uncertainty for a diagnosis of: 1)
infiltrative cardiomyopathy, 2) arrhythmogenic right ven-
tricular cardiomyopathy, 3) adult congenital heart disease
or 4) pericardial disease following standard HF care in-
cluding echocardiography [35]. Other tertiary sites may be
added in year two to three depending on recruitment
needs and registry sites may become randomization sites
if the experience and wait-time criteria are met.
Study population
We will recruit patients with either newly diagnosed HF
within the past 12 months or established HF patients
with deterioration/decompensation within the past 12
months.
Inclusion criteria:
Patients with new or worsening HF as above and:
1) age > 18 years
2) working clinical diagnosis (known or highly
suspected) of non-ischemic cardiomyopathy (NICM)
or clinical diagnosis of HFPEF (signs or symptoms of
heart failure with a LVEF ≥ 40%)
3) documented history of Class II-IV NYHA HF
symptoms within the past 12 months
Figure 1 Flow diagram for OUTSMART-HF. Abbreviations: HF = heart failure and CMR = cardiac magnetic resonance.
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1) prior CMR and no major change in clinical
condition
2) well-documented specific etiology (for example,
known amyloidosis or hemochromatosis)
3) physician considers cause of heart failure is
attributable to obstructive CAD
4) documented previous ST-segment elevation
myocardial infarction (STEMI) (any territory) or
non-ST-segment elevation myocardial infarction
(NSTEMI) in the left anterior descending
coronary artery territory
5) evidence of multi-vessel ischemia on stress
imaging
6) ongoing need for advanced heart failure support
(for example, inotropes or intra-aortic balloon
pump)
7) severe valvular heart disease requiring surgery
within the next six months
8) contraindications to CMR (for example, certain
metallic implants, severe claustrophobia)
9) contraindications to gadolinium contrast agent
(glomerular filtration rate < 30 ml/min/1.72 m2,
pregnancy)
10) severe medical conditions that significantly affect
the patient's outcome (for example, active
malignancy)
11) inability to give informed consentDescription of interventions (randomized and registry
participants)
Baseline: demographic and clinical data will be collected
from all participants on standardized case report forms.
This data will be collected from the participant and the
most recent, routine history and physical examination
that have been completed by the treating physician.
Quality of life questionnaires (Minnesota Living with
Heart Failure (MLHFQ) and EuroQoL Quality of Life
Scale (EQ5D)) will be administered. Patients at all sites
will undergo standard HF investigations according to
published Canadian guidelines [14,36,37]. Each center
will have a HF lead, an echo lead and a CMR lead as
well as a study co-ordinator.
Echocardiography
The performance and interpretation of echocardiography
will be carried out according to established Canadian
guidelines [38]. The echocardiography study and report
must include the following measures: left ventricular (LV)
size and systolic function (modified Simpson’s biplane
formula), LV diastolic function (E/e’), LV mass (Teichholz
formula), left atrial (LA) volume (biplane formula), val-
vular function (Doppler), right ventricular function, pul-
monary arterial pressures (if possible) and pericardial
assessment. Appendix A. The feasibility of implementing
these standards and collaboration among multiple centers
has been demonstrated in prospective echocardiography
trials such as the ASTRONOMER study [39]. The new
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obtained and measured as described [40]. A standardized
case report form will be completed by the echocardio-
grapher. The most likely HF etiology based upon the
echocardiogram will be provided to the referring
physician.
CMR
Following all HF investigations (including echocardio-
graphy), study participants randomized to routine CMR as
well as those requiring selective CMR will undergo a
conventional scan. The CMR protocol must include an
assessment of biventricular volumes and systolic function,
LV mass, LA volume (biplane formula), global and
regional myocardial edema using T2 weighted sequences,
and hyperemia and regional myocardial fibrosis using con-
trast enhanced T1 weighted sequences. Appendix A. CMR
interpreters participating in this trial should report a mini-
mum of 100 cases/year. Local CMR interpreters at each
participating center will be expected to complete a stan-
dardized clinical report form. The most likely HF etiology
based upon the CMR will be provided to the referring
physician. All CMR data acquisition and reporting will
conform to current published guidelines [41,42].
The echo and CMR reports will be integrated with the
other clinical data when used by the treating physician to
make a final clinical determination on the HF etiology.
Primary outcome measure - frequency of definitive
diagnoses
Following the completion of all baseline testing (including
echo ± CMR), the treating physician will assign a diagno-
sis on a standardized template using all available infor-
mation. The HF categories include: idiopathic dilated
cardiomyopathy, infiltrative cardiomyopathy, inflamma-
tory cardiomyopathy, hypertrophic cardiomyopathy, heart
failure with preserved ejection fraction (HFPEF), ischemic
cardiomyopathy, mixed etiology and other (for example,
pericardial disease, adult congenital heart disease, arrhy-
thmogenic right ventricular cardiomyopathy). The diagno-
sis of non-ischemic cardiomyopathies will be based upon
the 2008 Canadian Cardiovascular Society Consensus
conference guidelines [37].
Expected result
The routine CMR arm will have a significantly higher
rate of infiltrative, inflammatory, hypertrophic, ischemic,
mixed and other cardiomyopathies than the selective
CMR group.
Follow-up
Clinical outcomes will be collected by telephone follow-
up, and/or by hospital chart and electronic health record
review at three and twelve months and then yearly up tofour years, following completion of baseline scans. Data
will be recorded on standardized case report forms.
Quality of life questionnaires (MLHFQ and EQ5D) will
be administered at each follow-up.
Secondary outcome measures
(i) Treatment effects: at three months and one year,
the treating physician will be asked to reassess the
HF etiology. The presence of each HF medication
class will be re-assessed in addition to the overall
number of cardiac medications. The presence of
advanced HF therapies will additionally be recorded
at each follow-up visit including: implantable
device, electrophysiologic study/ablation, cardiac
surgery/transplantation, and disease specific
therapies (for example, phlebotomy for
hemochromatosis; steroids for sarcoidosis).
(ii) Clinical endpoints: Composite Clinical Endpoints
(CCE that is, death, cardiovascular (CV) death, HF
admission), left ventricular function, QoL, referral
to HF clinic, costs and safety will be assessed at
three months, then annually for a minimum of one
year and a maximum of four years.
Resource utilization and costs: regression methods
will be used to assess the incremental costs
associated with the routine use of CMR.(iii) Echo/CMR variability: anonymized copies of CMR
and echo studies will be sent to a core lab for
interpretation in approximately 10% of cases in
order to assess reproducibility and quality assurance
of the results. Appendix A.Statistical analysis
Descriptive statistics will be used to summarize the
characteristics of the patients for each imaging technol-
ogy on demographic, clinical and site related factors,
and differences between these groups will be reviewed
for their clinical significance.Analysis populations
For the purposes of data analysis, three study populations
will be considered: Intent-to-treat (ITT) population,
As-treated population and Per-protocol population.
The ITT population will be used for the main analysis
for all primary and secondary objectives, except for the
safety analysis where the As-treated population will
be used. As a secondary analysis, the analyses will
be repeated for the As-treated and Per-protocol
populations.
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For the primary analysis, the definitive diagnosis of
cardiomyopathy between routine CMR versus echo with
selective CMR, diagnosis will be compared using chi-
square techniques. Potential confounding variables of
the relationship between the imaging strategies and the
primary endpoint will be assessed. In particular, propen-
sity scores based on patient factors (for example, in/
outpatient, NYHA class, HF duration, diabetes, atrial
fibrillation) and site factors (for example, time-to-
imaging, time-to-therapy) will be used in the analysis if
necessary to adjust for potential differences. A logistic
regression model will be used to assess the occurrence
of the endpoints between the imaging strategies (model
will include a group indicator variable) adjusting for any
pertinent baseline differences identified.
Secondary outcomes
For the binary secondary outcomes, such as CCE, referral
to HF clinic and HF therapies, chi-square tests will be
used to compare the imaging strategies. Logistic regres-
sion analysis will be used for adjusting any pertinent
baseline differences identified. For continuous secondary
outcomes, such as LV function, MLHFQ and EQ5D, ana-
lysis of variance will be used to compare trends over time
between the imaging strategies. Analysis of covariance will
be used for adjusting any pertinent baseline differences
identified. For assessing the reproducibility of echo/CMR
results, reliability statistics, including intra-class correla-
tions and kappas, will be calculated to compare CMR and
echo studies with the core lab interpretations.
Economic evaluation
A cost minimization analysis comparing routine CMR
versus standard care (echocardiography plus selective
CMR) will be conducted. Analysis will be restricted to
the follow-up period within the study database and will
be conducted from the health care system perspective.
Regression analysis will provide 95% confidence intervals
around the estimate of incremental costs. In addition,
univariate sensitivity analysis will be conducted to assess
the robustness of the study’s results to changing assump-
tions related to the unit costs of specific resource items.
Safety analysis
Safety will be evaluated by documenting all adverse
events. Descriptive statistics (frequency distributions,
numerical descriptors) and 95% confidence intervals will
be calculated. The As-treated population will be the
main analysis population for this safety evaluation.
Missing data
‘Missingness’ is considered to be missing at random and
mixed methods repeated measures (MMRM) and multipleimputation techniques will be used for handling missing
data. In particular, for continuous outcomes at multiple
time points MMRM will be used.
Sample size justification
Based on a study of patients with NICM (prior to avai-
lability of CMR) a myocardial biopsy adds a specific
diagnosis to standard approaches in 15% of patients with
NICM increasing the rate from 35% to 50% [7]. For the
sample size determination, the estimated occurrence of a
definitive diagnosis with CMR is 50% and echo (with
selective use of CMR) is 35%. For the primary analysis
comparing routine CMR versus selective CMR with a
sample size of 252 per group is required to detect a dif-
ference in the event rate of definitive diagnosis of cardio-
myopathy of 35% (selective CMR) versus 50% (routine
CMR), based on the Z-test with a pooled variance
estimate, and after adjustment for 10% patient loss or
withdrawal, we will be able to detect a difference in the
event rate of definitive diagnosis of cardiomyopathy of
35% (selective CMR) versus 50% (routine CMR), a level
of significance of 0.05, power of 90% and an adjustment
for 10% patient loss or withdrawal.
Study management
The IMAGE-HF trial is managed by an Executive Com-
mittee consisting of clinicians specialized in diagnostic
imaging and/or heart failure and experts in biostatistics,
physics and radiochemistry, as well as a larger Steering
Committee consisting of members of the Executive
Committee and representatives of all the initial study
centers. In addition there is an events adjudication com-
mittee which will independently review and adjudicate
each clinical event blinded to treatment randomization.
Since all the imaging approaches are part of standard
clinical practice, no interim analysis is planned but there
will be an independent Data Safety Monitoring Board
(DSMB) which will review the safety data on a periodic
basis; the frequency of the meetings and the charter
governing the DSMB will be finalized at the first meeting
of the DSMB.
Discussion
Multicenter randomized controlled trials are needed to
evaluate the emerging role of advanced cardiac imaging in
heart failure. CMR is increasingly advocated as a useful
tool to evaluate the diagnosis and prognosis of non-
ischemic HF patients, but to date there is little evidence to
show that outcomes have improved. In IMAGE-HF 1-B,
Canadian and Finnish tertiary care sites with access to
CMR will randomize non-ischemic HF patients to routine
CMR in order to determine whether there are any gains
over current imaging strategies employing selective CMR
utilization. All patients in this trial will undergo a
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in HF guidelines.
The design of this trial has several appealing aspects:
First, we will evaluate the role of CMR in HF in a real
world setting. Given differences in MRI access, local
imaging expertise and in the interpretation of
guidelines, the use of CMR in non-ischemic HF can
vary greatly in a tertiary care setting. In the proposed
randomized trial, we will study whether routine CMR
offer any diagnostic gains over a more judicious
approach. Such a strategy will thus emulate centers
with open CMR access versus those without and
determine what if any impact this has on actual patient
management. All imaging studies, echo and CMR, will
be part of the overall clinical care received by the
patient. We also feel that the multicenter design with
varying level of CMR expertise and the inclusion of
new or worsening HF patients will provide a real world
experience.
Second, we will be able to determine whether CMR
diagnoses in non-ischemic HF differ from echo
diagnoses. The influence that the echo and CMR
diagnoses have on the treating physician’s HF diagnosis
will be examined. Also, the reproducibility of the
imaging diagnoses will be determined in 10% of CMRs
and echos as part of our quality assurance analysis.
Third, the potential for routine CMR to guide HF
pharmacotherapy and to initiate disease specific
treatment will be evaluated. CMR should uncover HF
etiologies, such as myocardial infiltration, that was not
previously detected by echo and other baseline testing.
The treating physician could then prescribe treatment
that is more tailored to the underlying pathology.
Fourth, we will determine the impact of routine CMR
on the outcomes of non-ischemic HF patients. Most
advanced cardiac imaging studies evaluate the
diagnostic accuracy of a given modality with no
assessment on patient outcome. In a secondary
analysis, we will evaluate clinical outcomes including: a
composite clinical end-point (death, CV death and HF
admission) and two quality of life surveys: MLHFQ and
EQ5D. We will also ascertain the feasibility of
implementing a routine CMR approach in terms of
safety and cost.
Limitations
Given that CMR provides insight into myocardial cha-
racterization, we expect that the etiology of heart failure
will be better characterized in those HF patients under-
going routine CMR. However, in some instances ad-
ditional investigations such as myocardial biopsy and
invasive hemodynamics may be required to confirm
CMR findings. Therefore, the final diagnosis of heartfailure etiology may ultimately be determined by CMR
driven ancillary testing. We will assess the impact of
downstream resource utilization on diagnosis and out-
come in the multivariable analysis as well as calculate
the additional cost burden.
Summary
In largely single center studies, CMR has been shown to
offer a diagnostic advantage in specific HF disease states
however its role in undifferentiated non-ischemic HF is
largely unknown. Thus IMAGE-HF is a clinically relevant
and timely study in an era of growing health costs and
increasing pressure for fiscal responsibility. Given the
available evidence and local experiences, we are confident
that routine CMR will offer diagnostic and therapeutic





Standardization and quality assurance (IMAGE-QA)
The IMAGE-HF QA program standardizes several
important aspects of clinical imaging:
1. defining best current imaging practice for standard-
care tests
2. disseminating advanced imaging technology and
standards
3. promoting structured reporting and comprehensive
imaging QA
4. ensuring consistent interpretation and patient
management recommendations
For the IMAGE-HF project 1-B (OUTSMART-HF),
this includes standard operating procedures (SOPs) for
echocardiography (ECHO) and cardiac magnetic reso-
nance (CMR), as well as structured reporting elements
and quality assurance review by QA-CORE labs (SOPs
and CRFs are posted on the IMAGE-HF website).
Standard-care imaging protocols
Echocardiography (ECHO):
IMAGE-HF 1-AB SOP ECHO-etiology (MHI)
Based on Montreal Heart Institute (MHI) CORE labora-
tory procedure manual for the IMAGE-HF 1-A study
(AIMI-HF): TECHNICAL GUIDE FOR ECHOCAR-
DIOGRAPHY October 2010 (E O’Meara, J-C Tardif).
Detailed procedures are described for the required para-
sternal, apical and sub-costal view measurements, and
instructions for transfer of DICOM format images to the
MHI CORE lab.
Advanced imaging protocols
Cardiac Magnetic Resonance (CMR):
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(CanSCMR)
Based on Canadian Society for Cardiovascular Magnetic
Resonance (CanSCMR) protocol recommendations v1.3
April 2009. Imaging parameters are included for assess-
ment of LV function, inflammation, fibrosis and mitral
valve regurgitation.
Common structured reporting elements
ECHO:
HF18C 1-B-etiology ECHO Report
The following parameters are included on the interpre-
tation CRF: LV structure, LV systolic and diastolic function
parameters, LV segmental wall-motion scores, RV struc-
ture and systolic function, severity of valve stenosis and
regurgitation. Clinical interpretation as selected from a list
of the most likely echocardiographic diagnoses, and con-
firmation that the diagnosis was communicated to the
referring physician, are captured on the CRF.
CMR:
HF19C 1-B-etiology CMR Report
The following parameters are included on the interpre-
tation CRF: LV and RV structure and systolic function
parameters, LV myocardial edema and hyperemia, LV
segmental wall-motion and tissue characterization scores,
severity of valve regurgitation, and assessment of peri-
cardial effusion. Clinical interpretation as selected from a
list of the most likely CMR diagnoses, and confirmation
that the diagnosis was communicated to the referring
physician, are captured on the CRF.
Quality assurance CORE lab reviews (QA-CORE)
A subset of scans (10%) are targeted for over-reading
interpretation at an experienced site identified as the
CORE lab for each imaging modality. The first two
scans (and 5% of the subsequent scans) from each
imaging modality at each recruiting site are transferred
to the corresponding modality QA-CORE lab for
clinical interpretation and comparison to the site inter-
pretation for quality assurance. Disagreements in the
overall ECHO or CMR diagnosis are resolved by subse-
quent consensus review between the site and CORE lab,
and recorded on the corresponding CRFs: HF18-QA,
HF19-QA.
The QA-CORE lab for ECHO is established at the
University of Ottawa Heart Institute, and the QA-CORE
lab for CMR is at the University of Alberta.
Additional file
Additional file 1: Table S1. IMAGE-HF Participating Sites.
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